Pharmaceuticals

Eyenovia

Eyenovia Completes $50 Million Private Placement and Updates OPTEJET Development Plan

Eyenovia Issues Cryptocurrency for Financing and Appoints New CIO

Eyenovia Inc. Secures Private Placement Financing to Acquire HYPE Tokens

EyeNovia Secures $50 Million Investment

Eyenovia Amends Loan Agreement and Rates by Spark

Eyenovia released FY2025 Q1 earnings on May 19 (EST), actual revenue USD 14.72 K (forecast USD 400 K), actual EPS USD -1.5914 (forecast USD -9.6)

Eyenovia and Betaliq Discuss Merger Agreement

Eyenovia Inc. Reports Q1 2025 Loss Narrowing and Plans Optejet Device Approval

Eyenovia Inc Expects to Report Quarterly Loss of $9.60 Per Share and 9900% Revenue Growth

Eyenovia Inc Preview: Expected EPS Loss of $9.60, Revenue to Increase by 9900%

Eyenovia Inc. Receives NASDAQ Non-Compliance Notice

Eyenovia released FY2024 Q4 earnings on April 15 (EST), actual revenue USD 28.09 K (forecast USD 1.597 M), actual EPS USD -16.4383 (forecast USD -8)

Eyenovia released FY2024 annual earnings on April 15 (EST), actual revenue USD 57.34 K (forecast USD 1.626 M), actual EPS USD -59.81 (forecast USD -49.6)

Eyenovia Expected to Report 32,467.6% Qtr Revenue Growth, But EPS Loss

Eyenovia Inc Expected Quarterly Revenue Growth of 32,467.6%

Eyenovia Inc expects a 32,467.6% revenue growth for the quarter ending December 31, 2024, with an EPS loss of $7.20

Eyenovia Inc expects 32,467.6% revenue growth for the quarter ending December 31, 2024, with a loss of $7.20 per share

Eyenovia Submits Late 10-K Report, Expects Significant Impairment

Eyenovia Inc Expected Revenue Growth of 32,467.6% in 2024 Quarterly Report

Eyenovia Signs Letter of Intent for Reverse Merger with Betaliq, Valuation at $77 Million

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Tradr 2X Long ASTS Daily ETF

Able View Global

Eli Lilly

ROCHE HOLDINGS AG

Roche

Astrazeneca

NOVARTIS AG

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Daiichi Sankyo

Otsuka Pharmaceutical

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap